Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy

Descrizione del progetto

Un innovativo substrato per il menisco contro l’artrosi

Gli interventi resettivi del menisco spesso portano ad artrosi precoce, che richiede strategie di ricostruzione alternative. Il progetto MEFISTO, finanziato dall’UE, propone lo sviluppo di un substrato basato su nanomateriali in grado di interagire con il tessuto meniscale nativo. Questo dispositivo innovativo favorirà la rivascolarizzazione locale e aiuterà la rigenerazione del menisco nativo, specialmente in pazienti più giovani. Al contempo, somministrerà i farmaci localmente per modulare l’infiammazione del tessuto in pazienti con artrosi avanzata. Visto il numero consistente di pazienti che si sottopongono a meniscectomia, gli interventi nell’ambito del progetto MEFISTO contribuiranno a migliorare l’esito postoperatorio e a ridurre le comorbilità legate all’artrosi.

Obiettivo

MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.

Invito a presentare proposte

H2020-NMBP-TR-IND-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-NMBP-TR-IND-2018

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

GEISTLICH BIOMATERIALS VERTRIEBSGESELLSCHAFT MBH
Contribution nette de l'UE
€ 37 500,00
Indirizzo
SCHNEIDWEG 5
76534 Baden-Baden
Germania

Mostra sulla mappa

Regione
Baden-Württemberg Karlsruhe Baden-Baden, Stadtkreis
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 361 250,00

Partecipanti (14)